Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

Brief summary

This study will assess the use of an active drug in adult patients with moderate to severe chronic plaque psoriasis and compare an active drug to other commonly used biologics.

Observational study

Chronic Plaque Psoriasis
2051 patients
Protocol ID:
Observational model:
Time perspective:

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female


18 Years and older.

Inclusion Criteria:

- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a
specialist and presence of moderate to severe psoriasis symptoms according to
physician's judgement at time of recruitment.

- Participant starting any approved treatment for psoriasis and physician's decision
must be reached prior to recruitment in the study.

- Participant willing to continue with study documentation after cessation of therapy.

Exclusion Criteria:

- Unwillingness or inability to comply with study requirements.

- Participation in an interventional clinical trial, concurrently or within the last 30
days. Participation in a post-market observational study (PMOS) or Registry is

All the cities where the clinical studies are located

Calgary - T3E 0B2

Edmonton - T5K 1X3

Edmonton - T6G 1C3

St. John's - A1A 4Y3

St. John's - A1C 2H5

St. John's - A1E 1V4

Ajax - L1S 7K8

Barrie - L4M 7G1

Hamilton - L8L 8E7

Hamilton - L8N 1Y2

Markham - L3P 1X2

Mississauga - L4W 0C2

Mississauga - L5H 1G9

Ottawa - K1H 7X3

Peterborough - K9J 5K2

Stoney Creek - L8G 1H1

Toronto - M2M 4J5

Waterloo - N2J 1C4

Whitby - L1N 8M7

Laval - H7N 6L2

Fredericton - E3B 1G9

Brandon - R7A 0L5